WO2001027277A3 - Proteins and polynucleotides encoded thereby - Google Patents

Proteins and polynucleotides encoded thereby Download PDF

Info

Publication number
WO2001027277A3
WO2001027277A3 PCT/US2000/028480 US0028480W WO0127277A3 WO 2001027277 A3 WO2001027277 A3 WO 2001027277A3 US 0028480 W US0028480 W US 0028480W WO 0127277 A3 WO0127277 A3 WO 0127277A3
Authority
WO
WIPO (PCT)
Prior art keywords
mbspx
polypeptides
proteins
polynucleotide
polypeptide
Prior art date
Application number
PCT/US2000/028480
Other languages
French (fr)
Other versions
WO2001027277A2 (en
Inventor
Richard A Shimkets
Henri Lichenstein
Ferenc L Boldog
Original Assignee
Curagen Corp
Richard A Shimkets
Henri Lichenstein
Ferenc L Boldog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Richard A Shimkets, Henri Lichenstein, Ferenc L Boldog filed Critical Curagen Corp
Priority to EP00970915A priority Critical patent/EP1222270A2/en
Priority to CA002386925A priority patent/CA2386925A1/en
Priority to JP2001530480A priority patent/JP2003529334A/en
Priority to AU80231/00A priority patent/AU8023100A/en
Publication of WO2001027277A2 publication Critical patent/WO2001027277A2/en
Publication of WO2001027277A3 publication Critical patent/WO2001027277A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention provides novel polypeptides, termed MBSPX polypeptides, as well as polynucleotides encoding MBSPX polypeptides and antibodies that immunospecifically bind to an MBSPX or a derivative, variant, mutant, or fragment of an MBSPX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the MBSPX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.
PCT/US2000/028480 1999-10-13 2000-10-13 Proteins and polynucleotides encoded thereby WO2001027277A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00970915A EP1222270A2 (en) 1999-10-13 2000-10-13 Proteins and polynucleotides encoded thereby
CA002386925A CA2386925A1 (en) 1999-10-13 2000-10-13 Proteins and polynucleotides encoded thereby
JP2001530480A JP2003529334A (en) 1999-10-13 2000-10-13 Proteins and polynucleotides encoded by them
AU80231/00A AU8023100A (en) 1999-10-13 2000-10-13 Proteins and polynucleotides encoded thereby

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15923199P 1999-10-13 1999-10-13
US60/159,231 1999-10-13
US17567000P 2000-01-12 2000-01-12
US60/175,670 2000-01-12
US68859800A 2000-10-12 2000-10-12

Publications (2)

Publication Number Publication Date
WO2001027277A2 WO2001027277A2 (en) 2001-04-19
WO2001027277A3 true WO2001027277A3 (en) 2002-04-18

Family

ID=27388285

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/028480 WO2001027277A2 (en) 1999-10-13 2000-10-13 Proteins and polynucleotides encoded thereby

Country Status (5)

Country Link
EP (1) EP1222270A2 (en)
JP (1) JP2003529334A (en)
AU (1) AU8023100A (en)
CA (1) CA2386925A1 (en)
WO (1) WO2001027277A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1311689A2 (en) * 2000-08-21 2003-05-21 Millennium Pharmaceuticals, Inc. Human carboxylesterase family member and uses thereof
CA2563735C (en) 2004-04-22 2020-07-14 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby
WO1998004697A1 (en) * 1996-07-26 1998-02-05 Mount Sinai School Of Medicine Of The City Cdo tumor suppressor gene and protein
WO2000012708A2 (en) * 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
WO2001019856A2 (en) * 1999-09-13 2001-03-22 Curagen Corporation Secreted human proteins, polynucleotides encoding them and methods of using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby
WO1998004697A1 (en) * 1996-07-26 1998-02-05 Mount Sinai School Of Medicine Of The City Cdo tumor suppressor gene and protein
WO2000012708A2 (en) * 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
WO2001019856A2 (en) * 1999-09-13 2001-03-22 Curagen Corporation Secreted human proteins, polynucleotides encoding them and methods of using the same

Also Published As

Publication number Publication date
WO2001027277A2 (en) 2001-04-19
JP2003529334A (en) 2003-10-07
CA2386925A1 (en) 2001-04-19
AU8023100A (en) 2001-04-23
EP1222270A2 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
WO2001092523A3 (en) Human polynucleotides and polypeptides encoded thereby
WO2000058473A3 (en) Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2001007595A3 (en) Novel fibroblast growth factor and nucleic acids encoding same
WO2001036645A3 (en) Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same
WO2000053742A3 (en) Polynucleotides and proteins encoded thereby
WO2002066647A3 (en) Type 2 ctokine receptor and nucleic acids encoding same
WO2001049729A8 (en) Novex polypeptides, nucleic acids encoding same and their diagnostic and therapeutic use
WO2001074856A3 (en) Wnt-7b-like polypeptides and nucleic acids encoding same
WO2002002625A3 (en) Novel fibroblast growth factors and nucleic acids encoding same
WO2001062928A3 (en) Polypeptides and nucleic acids encoding same
WO2001070978A3 (en) Polypeptides and nucleic acids encoding same
WO2001061009A3 (en) Polypeptides and nucleic acids encoding same
WO2003025147A3 (en) Novel polynucleotides and proteins encoded thereby
WO2001044473A3 (en) Polypeptides and nucleic acids encoding same
WO2001036638A3 (en) Polypeptides and nucleic acids encoding same
WO2000061754A3 (en) Human proteins and polynucleotides encoding them
WO2000070046A3 (en) Secreted polypeptides and corresponding polynucleotides
WO2001085767A3 (en) Human proteins polynucleotides encoding them and methods of using the same
WO2001023561A3 (en) Novel polynucleotides encoding proteins containing thrombospondin type 1 repeats
WO2001023572A3 (en) Polynucleotides and polypeptides encoded thereby
WO2001068851A3 (en) Polypeptides and nucleic acids encoding same
WO2001027277A3 (en) Proteins and polynucleotides encoded thereby
WO2003040345A3 (en) Type 2 cytokine receptor and nucleic acids encoding same
WO2001032874A3 (en) Polypeptides and nucleic acids encoding same
WO2000075321A3 (en) Polynucleotides and membrane-bound polypeptide encoded thereby

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2386925

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 80231/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 530480

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000970915

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000970915

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000970915

Country of ref document: EP